ARCA Logo - JPEG.jpg
ARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis
August 09, 2017 16:30 ET | ARCA Biopharma, Inc.
ARCA Estimates Reporting Top-line Phase 2B Data in the First Quarter of 2018Gencaro Development Program Has Been Granted Fast Track Designation by U.S. FDA WESTMINSTER, Colo., Aug. 09, 2017 (GLOBE...
american-health-council-logo-210x126.jpg
American Health Council Names Edmund J. Miller, Ph.D. to Education Board
July 28, 2017 08:00 ET | American Health Council
NEW YORK, July 28, 2017 (GLOBE NEWSWIRE) -- Dr. Edmund J. Miller of The Feinstein Institute for Medical Research has been selected to join the Education Board at the American Health Council. He will...
admera_health_final_logo_transparent_final.jpg
Admera Health Partners with Helix to Launch Genetic Tests to Assess the Risk of Inherited High Cholesterol, Sudden Cardiac Death, and Inherited Diabetes
July 24, 2017 07:45 ET | Admera Health, LLC
SOUTH PLAINFIELD, N.J., July 24, 2017 (GLOBE NEWSWIRE) -- Admera Health, a molecular diagnostics company developing comprehensive genetic tests for the risk assessment and early diagnosis of...
Abiomed Logo
New Study with Abiomed’s Impella 2.5® Heart Pump Demonstrates Potential Survival with Pre-PCI Insertion in Heart Attacks with the Left Main Coronary Artery
June 30, 2017 08:04 ET | Abiomed
DANVERS, Mass., June 30, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today the recent publication of a...
Heart Recovery Patients Visit Capitol Hill to Advocate for Lifesaving Cardiovascular Technology
June 09, 2017 08:07 ET | Abiomed
WASHINGTON, June 09, 2017 (GLOBE NEWSWIRE) -- Nineteen patients who benefitted from treatment with Abiomed’s Impella heart pumps traveled to Washington, D.C. on June 8, 2017, to meet with elected...
ARCA Biopharma Announces First Quarter 2017 Financial Results and Provides Business Update
May 15, 2017 08:30 ET | ARCA Biopharma, Inc.
WESTMINSTER, Colo., May 15, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
Abiomed Introduces 3rd Generation Impella CP® Heart Pumps at SCAI 2017
May 09, 2017 09:33 ET | Abiomed
DANVERS, Mass., May 09, 2017 (GLOBE NEWSWIRE) -- Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced the debut of the 3rd Generation...
admera_health_final_logo_transparent_final.jpg
Health in Code’s Novel Work Published In JACC, Helps Increase Sensitivity Detection for Admera Health’s CardioGxOne™ Test Regarding Patients with High-Risk Dilated and Arrhythmogenic Cardiomyopathies
May 03, 2017 09:13 ET | Admera Health, LLC
A CORUÑA, Spain and SOUTH PLAINFIELD, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- Today, Health in Code (HiC), (www.healthincode.com) a thought leader in the genetic cardiovascular field announced...
New Elsevier Book Examines Complex Mechanisms Relating to Cardiac Diseases from Pathophysiological and Clinical Viewpoints
April 05, 2017 04:00 ET | Elsevier, Inc.
CAMBRIDGE, MA--(Marketwired - April 05, 2017) - Elsevier, the information analytics company specializing in science and health, today announced the publication of The Heart in Rheumatic, Autoimmune...
Abiomed Logo
First-Ever Presentation on Abiomed’s Impella® Quality (IQ) Assurance Program and Importance of Treatment Protocols to Improve Patient Survival and Heart Recovery at the 2017 American College of Cardiology Scientific Session
March 19, 2017 14:30 ET | Abiomed
- Real-World Data Representing 15,259 Patients WASHINGTON, March 19, 2017 (GLOBE NEWSWIRE) -- Data from Abiomed’s (NASDAQ:ABMD) Impella® Quality (IQ) Assurance Program, which includes the IQ...